Workshops
Mark your calendar and add our workshops to your list of must-see activities at AACC.
Novel Biomarkers in the US for Management of Preeclampsia
Wednesday, July 26, 2023
2:45 to 3:45 p.m.
Exhibit Hall Theater #1
Learn from our two speakers about the new biomarkers PlGF, sFlt-1 and CgA that can help manage preeclampsia and neuroendocrine tumors.
Preeclampsia is a life-threatening pregnancy complication affecting eight percent of pregnant women in the US. PlGF and sFlt-1 help identify hospitalized women who may progress to a severe form of preeclampsia, improving clinical management.
Anders Berg
Associate Professor, Pathology and Biomedical Sciences
Associate Director, Clinical Chemistry
Cedars-Sinai Medical Center
Catherine Basso
Senior Regional Marketing Manager
Thermo Fisher Scientific
Andrea Gartner
Product Marketing Manager
Thermo Fisher Scientific
Learning objectives
- Learn how PlGF and sFlt-1 can be used for the stratification of preeclampsia in hospitalized patients
- Understand the value of KRYPTOR and TRACE technology for clinical decisions
New Solutions for Fast and Sensitive Nucleic Acid Detection in Inhibitor-Containing Conditions
Wednesday, July 26, 2023
10:30 to 10:50 a.m.
Exhibit Hall Theater #2
During this session, we will present two new product offers from Thermo Fisher Scientific. First, a new direct RT-qPCR system that can be used to amplify nucleic acid from inhibitor-enriched samples. Our latest data demonstrates new reagents and workflow conditions that work best on saliva and serum samples.
Second, we will discuss the new Invitrogen™ Lyo-ready Bst DNA Polymerase for RT-LAMP isothermal amplification. This best-in-class enzyme demonstrates the highest speed, sensitivity, and resistance to inhibitor performance in LAMP reactions. Together, the Invitrogen™ Lyo-ready SuperScript™ IV Reverse Transcriptase and Invitrogen™ Lyo-ready RNaseOUT™ RNase Inhibitors offer the fastest solution for pathogen diagnostics using RT-LAMP.
Agnė Alminaitė
Product Manager
Thermo Fisher Scientific
Learning objectives
- Learn about the new offers for direct PCR- and LAMP-based diagnostics
- Learn about more effective workflows to perform direct RT-qPCR from challenging samples
- Learn about the newly released, best-in-class Invitrogen Lyo-ready Bst DNA Polymerase for LAMP
Showcasing emerging healthcare trends and technologies with LC-MS
Wednesday, July 26, 2023
7:00 to 8:30 a.m.
Room: Hilton Hotel | California B, 2nd Floor
Accurate and rapid performance of medical diagnostic tests is desired for enhanced clinical decision making. Integration of LC-MS in the healthcare space continues to drive innovation and is crucial for progress in this field. Speakers will discuss novel sample separation and analysis strategies in two growing fields—clinical metabolomics and clinical toxicology. Concepts of accuracy, precision and specificity alongside use of high field asymmetric ion mobility (FAIMS) and combined with MS as a filtering technique will be shown to enhance project quality for global metabolomics initiatives. Next, novel sampling technologies that include automated dried blood spot (DBS) analysis and direct, non-invasive analysis with MS Pen technology will be shown for MS-based toxicology testing.
Robin Kemperman, Ph.D.
Senior Mass Spectrometrist
Children’s Hospital of Philadelphia
William Clarke, Ph.D.
Professor of Pathology
Johns Hopkins University School of Medicine
Tanis Correa
Senior Manager, Clinical Research Marketing
Thermo Fisher Scientific
Learning objectives
- Understand advantages and challenges in clinical metabolomics and how precision studies can assist
- Expand the knowledge of ion mobility spectrometry and its potential for clinical diagnostics in combination with mass spectrometry
- Discuss the advantages of novel sampling technologies (automated DBS and MS Pen) for rapid, accurate and non-invasive toxicology testing
Diomni: The Power of One
Date: Wednesday, July 26, 2023
Time: 12:30 to 12:50 p.m.
Room: Exhibit Hall Theater #2
Experience the power of one.
One connection: Diomni Enterprise Software combines instruments, assays, and consumables to streamline your workflow from samples to clinical results. It also lets you optimize your Applied Biosystems™ QuantStudio™ instruments, scaling and expanding your test menu at any time.
One interface: Flexible, multimode workspaces enable labs to use a single, intuitive user interface no matter the task—from performing routine testing to using test development tools. The assay development file (ADF) workflow provides a consistent user experience, and laboratory information system (LIS) integration may reduce time to results.
One workflow: Extraction, assay selection, testing, analysis, quality control (QC), and interpretive reporting are all integrated in a seamless, end-to-end workflow that helps improve efficiency while reducing the potential for human error from manual steps. This also helps reduce turnaround time with results available in approximately three hours. In this new era of digitalized workflows, Diomni Enterprise Software powerfully connects the components of your lab’s qPCR system into a single, easy-to-use solution.
Gloria Lam
Thermo Fisher Scientific
Learning objectives
- Understand how a digital workflow solution can streamline lab efficiency
- Define what Diomni can do for a lab
- Experience the power of one
EliA Autoimmune Diagnostics: Assay Design and Impact on Value-Based Care
Date: Tuesday, July 25, 2023
Time: 1:30 to 1:50 p.m.
Room: Exhibit Hall Theater #2
Autoimmune diseases impact one in five Americans and cost patients roughly $100 billion annually. The ability to diagnose patients early in the course of a disease and with increased accuracy is a critical component to mitigating associated burdens and costs. Understanding the nuances in the design of diagnostic tests, which can improve early and accurate diagnosis, is a necessary consideration as health systems and laboratories look to positively impact the cost and quality-of-life burden associated with autoimmune diseases at a population level.
Veena Joy, MSc, PhD
Thermo Fisher Scientific
Nadja Hoefs, PhD
Thermo Fisher Scientific
Learning objectives
- Understand the design of EliA rheumatoid arthritis and anti-phospholipid syndrome (APS) tests and the associated clinical and economic impact
- Examine the components of diagnostic tests which should be considered during autoimmune disease testing
- Illustrate the health and economic burden associated with autoimmune diseases in the United States